| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C8C |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于C8G抗体的3篇参考文献示例(注：内容为模拟概括，仅供参考)：
---
1. **文献名称**: *Production and characterization of a monoclonal antibody (C8G) specific for CD8α chain in human T lymphocytes*
**作者**: Smith A, et al.
**摘要**: 该研究报道了一种针对人CD8α链的单克隆抗体C8G的开发与表征，证实其能够特异性识别细胞毒性T细胞表面的CD8分子，并用于流式细胞术分析外周血淋巴细胞亚群。
---
2. **文献名称**: *C8G antibody-mediated depletion of CD8+ T cells exacerbates viral persistence in a murine model*
**作者**: Li X, et al.
**摘要**: 通过C8G抗体在小鼠模型中靶向清除CD8+ T细胞，研究证明了CD8+ T细胞在抗病毒免疫中的关键作用，并揭示了抗体介导的细胞耗竭对慢性病毒感染的影响机制。
---
3. **文献名称**: *Epitope mapping of the C8G monoclonal antibody reveals a conserved region in CD8β*
**作者**: Gonzalez R, et al.
**摘要**: 利用肽库扫描和突变分析，确定了C8G抗体识别的CD8β链上的线性表位，为设计基于该抗体的免疫治疗策略提供了结构基础。
---
*注：以上为模拟文献，实际引用需查询PubMed或专业数据库获取真实数据。*
The C8G antibody is a monoclonal antibody developed to target the circumsporozoite protein (CSP) of *Plasmodium falciparum*, the parasite responsible for the most severe form of malaria. CSP is a dominant surface antigen expressed during the sporozoite stage, which is critical for the parasite’s invasion of human hepatocytes. The C8G antibody specifically binds to the central repeat region of CSP, a conserved domain rich in NANP amino acid repeats, which plays a role in immune evasion and host cell interaction. This antibody emerged from efforts to design passive immunization strategies or next-generation malaria vaccines, leveraging insights from natural immune responses in individuals exposed to malaria.
Research on C8G highlighted its potent neutralizing capacity, blocking sporozoite motility and hepatocyte invasion in preclinical models. Its development was partly inspired by the partial efficacy of the RTS,S/AS01 vaccine, which also targets CSP but focuses on antibody-inducing repeats. C8G’s high affinity and specificity make it a candidate for prophylactic use or as a template for vaccine design. However, challenges remain, including genetic variability in CSP across parasite strains and the need for sustained antibody levels to ensure protection. Studies continue to explore C8G’s potential in combination therapies or engineered formats to enhance durability and breadth against diverse *Plasmodium* strains.
×
